Measuring the economic burden of neuromyelitis optica spectrum disorder in Colombia.
Mult Scler Relat Disord
; 82: 105376, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38141561
ABSTRACT
OBJECTIVE:
To assess the economic burden of neuromyelitis optica spectrum disorder (NMOSD) in the Colombian context.METHODS:
Analyses were conducted from a societal perspective using the prevalence-based approach. Costs were expressed in 2022 US dollars (1 USD = $3,914.46 COP). Direct medical costs were assessed from a bottom-up approach. Indirect costs included loss of productivity of the patient and their caregivers. The economic burden of NMOSD in Colombia was estimated as the sum of direct and indirect costs.RESULTS:
The direct cost of treating a patient with NMOSD was USD$ 8,149.74 per year. When projecting costs nationwide, NMOSD would cost USD$ 7.2 million per year. Of these costs, 53.5% would be attributed to relapses and 34.4% to pharmacological therapy. Indirect costs potentially attributed to NMOSD in Colombia were estimated at USD$ 1.5 million per year per cohort. Of these, 78% are attributable to loss of patient productivity, mainly due to reduced access to the labor market and premature mortality.CONCLUSIONS:
The NMOSD has a representative economic burden at the patient level, with direct costs, particularly related to relapses and medicines, being the main component of total costs. These findings are useful evidence that requires attention from public policymakers in Colombia.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neuromielitis Óptica
/
Costos de la Atención en Salud
Límite:
Humans
País/Región como asunto:
America do sul
/
Colombia
Idioma:
En
Revista:
Mult Scler Relat Disord
Año:
2024
Tipo del documento:
Article
País de afiliación:
Colombia
Pais de publicación:
Países Bajos